MorphoSys AG has decided to consolidate the drug discovery activities of its recent US acquisition, Constellation Pharmaceuticals, in Germany resulting in a non-cash impairment charge of €231 million. The decision, announced on 10 March, contributed to an operating loss in both the 2021 fourth quarter and full year, the company announced on 16 March.
